Drugs News and Research

RSS

Synaptophysin controls replacement of vesicles

A University of Wisconsin-Madison research team has solved a 25-year mystery that may lead to better treatments for people with learning deficits and mental retardation.

9 Jun 2011

Celerion earns ANVISA certification to conduct clinical research operations in Belfast, Lincoln

Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, and its clinical research and bioanalytical services operations in Lincoln, Nebraska USA, have been certified by the Brazilian National Health Surveillance Agency.

9 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

9 Jun 2011

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

IPS examines negotiations over intellectual property laws affecting generic AIDS drugs

Inter Press Service examines how "moves by developed nations such as the United States to tighten intellectual property laws are threatening to limit production and distribution of generic drugs, which experts say have been and will remain key in the prevention and treatment of HIV/AIDS and currently account for 80 percent of HIV/AIDS treatment."

9 Jun 2011

New research finds 74% drop in myocardial infarction over 20-year period

Better control of cholesterol levels and blood pressure and a decline in smoking have contributed to a 74% drop in the risk of heart attack among nearly 10,000 civil servants working in London over a 20-year period, according to new research.

9 Jun 2011

Children who experience trauma more likely to have behavior and learning problems

New research has shown that children's risk for learning and behavior problems and obesity rises in correlation to their level of trauma exposure, says the psychiatrist at the Stanford University School of Medicine and Lucile Packard Children's Hospital who oversaw the study.

9 Jun 2011

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation announced today that the FDA has accepted an Investigational New Drug (IND) application for APC-100 to treat prostate cancer (PCa).

9 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

Childhood trauma linked to higher rates of mental health problems and obesity, says Stanford/Packard psychiatrist

New research has shown that children’s risk for learning and behavior problems and obesity rises in correlation to their level of trauma exposure, says the psychiatrist at the Stanford University School of Medicine and Lucile Packard Children’s Hospital who oversaw the study. The findings could encourage physicians to consider diagnosing post-traumatic stress disorder rather than attention deficit/hyperactivity disorder, which has similar symptoms to PTSD but very different treatment.

8 Jun 2011

Therapeutic equivalent to replace penicillin

Antibiotics are among the greatest achievements of medical science. But lately the former multi-purpose weapon fails in the battle against infectious diseases. Bacteria are increasingly developing resistance to antibiotics. Researchers have now found a therapeutic equivalent which could replace penicillin and related phamaceuticals.

8 Jun 2011

Novation recognizes APP with NOVAPLUS Pharmacy Manufacturer of the Year

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., has been named NOVAPLUS Pharmacy Manufacturer of the Year by Novation, the industry's leading supply contracting company.

8 Jun 2011

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.

8 Jun 2011

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods.

8 Jun 2011

New research on spinal muscular atrophy

Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences, researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies."

8 Jun 2011

Scientists find neuronal cells die in Alzheimer's disease

In what they are calling a new direction in the study of Alzheimer's disease, UC Santa Barbara scientists have made an important finding about what happens to brain cells that are destroyed in Alzheimer's disease and related dementias.

8 Jun 2011

Self-assembling mini devices now enlisted in nanomedicine revolution

Measured in billionths of a meter, self-assembling nano-sized devices designed to carry drugs and imaging agents into the body are revolutionizing medicine by improving drug solubility and bio-distribution, providing a platform for combining targeting and imaging agents, and enabling membrane barriers to be crossed as well as making drug and imaging agent combination therapies possible.

8 Jun 2011

Doctors place greater value on life-prolonging treatments rather than on quality-enhancing ones

Doctors are more apt to recommend a more costly therapy to patients if it were determined to prolong the patient's life rather than just improve quality, according to a recent study from Medical Decision Making (published by SAGE).

8 Jun 2011

Drugs News and Research

Synaptophysin controls replacement of vesicles

Celerion earns ANVISA certification to conduct clinical research operations in Belfast, Lincoln

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

IPS examines negotiations over intellectual property laws affecting generic AIDS drugs

New research finds 74% drop in myocardial infarction over 20-year period

Children who experience trauma more likely to have behavior and learning problems

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Childhood trauma linked to higher rates of mental health problems and obesity, says Stanford/Packard psychiatrist

Therapeutic equivalent to replace penicillin

Novation recognizes APP with NOVAPLUS Pharmacy Manufacturer of the Year

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New research on spinal muscular atrophy

Scientists find neuronal cells die in Alzheimer's disease

Self-assembling mini devices now enlisted in nanomedicine revolution

Doctors place greater value on life-prolonging treatments rather than on quality-enhancing ones

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News